5 citations
,
January 2005 in “Journal of Enzyme Inhibition and Medicinal Chemistry” This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.
November 2021 in “Pharmaceutical Sciences” This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.
September 2020 in “Current Enzyme Inhibition” In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.
5 citations
,
January 2018 in “Research Journal of Pharmacy and Technology” In this rat study, finasteride treatment significantly reduced body, testis, epididymis, and prostate weights and affected testicular histology, indicating potential negative impacts on testicular function.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.